Photo Credit: EVGEN_PROZHYRKO
The Following is a summary of “Non-Allergic Urticarial Skin Reactions Associated with Mov18 Ige, First-In-Class Ige Antibody Recognism Folate Alpha,” Published in the March 2025 Issue of European Journal of Allergy and Clinical Immunology by Stavraka et al.
IGE Antibodies Targeting Cancening Antigens Showed Strong Anti-Tumor Effects. MOV18 IgE, Recognizing Folate Receiver Alpha (FRα), Showed Early Effficacy with Mill Urticarial Reactions.
RESEARCHERS DRIVED A RETROSPTIVE STUDY ON IMMUMUNOLOGICAL AND ALLERGIC Responses Linked to URTICARIAL REACTIONS IN PATENTS TREATED WITH MOV18 IGE.
Then Analyzed Frα Expression and Mov18 IgE Reactivity in Human Skin Using Immunohistochemistry, Immunofluorescence, and Immuno-Mam Spectrometry. They conduct transcriptomic Analyses on Paired Lessional and Non-Leesonal Biopsies from 1 Patient. They Assessed Systemic Markers, Including Cytokines, β-Tryptase, and Basophil Activation, Throughout the trial and during the reaction.
The Results Showed That 62.5% of 24 Patients Treated with Ige Deved Transient Urticarial Reactions During the First Infusion, Decreasing with Subsequent doses, with no β-Tryptase Elevation or Allergic Signs. In the FRα Expression or MOV18 Ige Binding was Found in Human Skin. In the Highest-Patient-Patient, Lesion Biopsies Showed Scattered Eosinophils, Neutrophils, and Mast Cell Degranulaation Without Increeed Imamune Infiltration. Transcriptomic Analysis Indicated pro-inflammory but not allergic Pathway Activation, with Systemic Allergic Mediators or Basophil Activation Detected.
Investigators Found that urticarial reactions after mov18 ige treatment were unlikely due to allergic mechanisms or skinn antigen recognition. They concluded that the reations resembled infusion-relaced effects seen with monoclonal antibodies.
